Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update Summary-Reference-Cited by-同舟云学术

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update Summary

Published:2018-08 Issue:8 Volume:14 Page:508-510
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Denduluri Neelima¹,Somerfield Mark R.¹,Giordano Sharon H.¹

Affiliation:

1. Virginia Cancer Specialists, the US Oncology Network, Arlington, VA; American Society of Clinical Oncology, Alexandria, VA; University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.18.00207

Reference5 articles.

1. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

2. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

3. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

4. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

5. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab Therapy by PSL;Pharmacogenomics and Personalized Medicine;2022-03

2. Adjuvant Therapy;Modern Breast Cancer Imaging;2021-11-01

3. Antibody–Drug Conjugates for the Treatment of Breast Cancer;Cancers;2021-06-09

4. Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research;Current Medicinal Chemistry;2021-06-08

5. Prognostic and predictive parameters in breast pathology: a pathologist’s primer;Modern Pathology;2020-11-05